Generation of a homozygous TIGIT gene knockout (TIGIT<sup>−/−</sup>) human iPSC line (MUSIi001-A-3) using CRISPR/Cas9 system

Simple item page
dc.contributor.authorSrisantitham J.
dc.contributor.authorSuwanpitak S.
dc.contributor.authorThongsin N.
dc.contributor.authorWattanapanitch M.
dc.contributor.correspondenceSrisantitham J.
dc.contributor.otherMahidol University
dc.date.accessioned2024-11-06T18:25:39Z
dc.date.available2024-11-06T18:25:39Z
dc.date.issued2024-12-01
dc.description.abstractAdoptive cell therapy for solid cancers involves enhancing and reinfusing immune cells to target tumor cells. The advancement of induced pluripotent stem cell technology enables the generation of immune cell products like T and NK cells for ACT. However, the expression of inhibitory receptors, such as TIGIT, may limit the functionality of these immune effector cells. In this study, we generated a homozygous TIGIT gene knockout iPSC line to potentially prevent inhibitory signaling and exhaustion, thereby creating potent “off-the-shelf” immune cell products for cellular immunotherapy applications. This approach could offer a new frontier in the fight against solid tumors.
dc.identifier.citationStem Cell Research Vol.81 (2024)
dc.identifier.doi10.1016/j.scr.2024.103601
dc.identifier.eissn18767753
dc.identifier.issn18735061
dc.identifier.scopus2-s2.0-85207596631
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/101903
dc.rights.holderSCOPUS
dc.subjectBiochemistry, Genetics and Molecular Biology
dc.titleGeneration of a homozygous TIGIT gene knockout (TIGIT<sup>−/−</sup>) human iPSC line (MUSIi001-A-3) using CRISPR/Cas9 system
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85207596631&origin=inward
oaire.citation.titleStem Cell Research
oaire.citation.volume81
oairecerif.author.affiliationSiriraj Hospital

Files

Collections

Scopus 2024